• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

AcuCort

0.45 SEK

-32.69 %

Less than 1K followers

ACUC

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-32.69 %
-36.48 %
-23.82 %
-24.83 %
-23.17 %
-38.56 %
-53.66 %
-85.02 %
-82.33 %

AcuCort is a pharmaceutical company. The company develops and commercializes pharmaceuticals based on well-established substances with a focus on user-friendliness and ease of administration. The company's leading product is an oral film for the acute treatment of allergic reactions and other conditions with high medical demand. Products are aimed at patients and caregivers globally. AcuCort was founded in 2006 and is headquartered in Lund, Sweden.

Read more
Market cap
105.73M SEK
Turnover
1.81M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
12.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/17/2026, 8:33 AM

AcuCort AB: AcuCort publishes newsletter with CEO update

AcuCort
Press release6/11/2026, 10:55 AM

AcuCort to attend BIO International Convention in San Diego - focus on strategic partnering discussions

AcuCort
Press release5/27/2026, 6:00 AM

AcuCort AB: AcuCort publishes newsletter with CEO update

AcuCort

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release4/16/2026, 2:06 PM

AcuCort AB: AcuCort publishes newsletter with CEO update

AcuCort
Regulatory press release4/13/2026, 6:20 AM

AcuCort AB: AcuCort and the FDA agree on iPSP - important step towards US market approval

AcuCort
Press release3/27/2026, 7:30 AM

AcuCort AB: AcuCort publishes newsletter with CEO update

AcuCort
Press release3/5/2026, 8:06 AM

AcuCort AB: AcuCort to participate in Bio Europe Spring - focus on international partnerships

AcuCort
Regulatory press release1/22/2026, 7:07 AM

AcuCort AB: AcuCort signs commercial agreement with Glenmark Pharmaceuticals for Germany and five additional European countries

AcuCort
Regulatory press release12/8/2025, 7:13 AM

AcuCort AB: AcuCort Secures New Order for Zeqmelit® - Continued Growth Across the Nordics

AcuCort
Regulatory press release11/28/2025, 9:00 AM

AcuCort AB: AcuCort appoints nomination committee

AcuCort
Regulatory press release10/14/2025, 11:00 AM

AcuCort AB: AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director

AcuCort
Regulatory press release9/25/2025, 7:28 AM

AcuCort AB: AcuCort granted extended SME status by the European Medicines Agency (EMA)

AcuCort
Press release9/18/2025, 6:30 AM

AcuCort AB: AcuCort's CEO to present at Life Science Conference in Copenhagen

AcuCort
Regulatory press release8/12/2025, 11:54 AM

AcuCort AB: Sales of Zeqmelit® commenced in Denmark

AcuCort
Regulatory press release6/18/2025, 4:43 PM

AcuCort AB: LSIF invests SEK 1 million in AcuCort through exercise of warrants - strong support ahead of final day for exercising TO 2

AcuCort
Regulatory press release6/17/2025, 11:27 AM

AcuCort AB: AcuCort signs Letter of Intent (LOI) with Glenmark Pharmaceuticals for Germany and five additional European countries

AcuCort
Regulatory press release6/10/2025, 6:30 AM

AcuCort AB: AcuCort signs Letter of Intent (LOI) with Lunatus for the Middle East and Gulf States

AcuCort
Regulatory press release5/26/2025, 11:00 AM

AcuCort AB: AcuCort's drug Zeqmelit® registered as a trademark in Canada

AcuCort
Regulatory press release5/12/2025, 6:00 AM

AcuCort AB: AcuCort receives new order for Zeqmelit® - strong development in the Nordic market

AcuCort